Compare Schwab US Large Cap Growth ETF (SCHG) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schwab US Large Cap Growth ETF vs GeneDx Holdings Corp — how do they compare? Schwab US Large Cap Growth ETF trades at $34.27, while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Schwab US Large Cap Growth ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| SCHG | WGS | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $35.30 | $167.51 |
52-Week Low | $28.10 | $34.51 |
Market Cap | — | $1.80B |
Enterprise Value | — | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SCHG trades at $34.15, down 0.09% on the day, with a neutral technical signal. The ETF offers concentrated exposure to U.S. large-cap growth stocks, particularly in technology and AI-driven sectors, with a low 0.04% expense ratio. Recent institutional buying includes a 7.3% position increase by Alpha Zero LLC (Defense World, July 21, 2026).
Outlook remains mixed; strong fundamentals and AI growth potential support long-term gains, but high concentration in top holdings and elevated valuations near 32x P/E pose risks. Market sentiment is divided between bullish growth prospects and concerns over reliance on mega-cap performance.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
